<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166610">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042898</url>
  </required_header>
  <id_info>
    <org_study_id>TRICSIII</org_study_id>
    <secondary_id>301852</secondary_id>
    <nct_id>NCT02042898</nct_id>
  </id_info>
  <brief_title>Transfusion Requirements in Cardiac Surgery III</brief_title>
  <acronym>TRICS-III</acronym>
  <official_title>An International, Multi-centre, Randomized Controlled Trial to Assess Transfusion Thresholds in Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <authority>Canada: Canadian Institutes of Health Research</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRICS-III is an international, multi-centre, open-label randomized controlled trial of two
      commonly used transfusion strategies in high risk patients having cardiac surgery using a
      non-inferiority trial design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Composite score of any one of the following: (1) all-cause mortality; (2) myocardial infarction; (3) new renal failure requiring dialysis; or (4) new focal neurological deficit</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite score of any one of the following events occurring during the index hospitalization (from the start of surgery until hospital discharge or postoperative day 28, whichever comes first): (1) all-cause mortality; (2) myocardial infarction; (3) new renal failure requiring dialysis; or (4) new focal neurological deficit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital all-cause mortality</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital myocardial infarction</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital new renal failure requiring dialysis</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital new focal neurological deficit</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the ICU and hospital</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged low output state  defined as the need for two or more inotropes for 24 hours or more, intra-aortic balloon pump postoperatively or ventricular assist device</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Infection will be defined as septic shock with positive blood cultures, pneumonia defined as roentgenographic infiltrate and two of three criteria: fever, leukocytosis, and positive sputum culture, and/or deep sternal or leg wound infection requiring intravenous antibiotics and/or surgical debridement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury (defined by Kidney Disease Improving Global Outcomes criteria)</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Acute kidney injury:defined by the Kidney Disease Improving Global Outcomes clinical practice guideline (KDIGO) as
a 50% increase in serum creatinine within 7 days;
a 26.5 Âµmol/L (0.3mg/dl) or greater increase within 48 hours; or
urine volume less than 0.5 ml/kg/h for 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gut infarction</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Gut infarction confirmed by imaging (e.g. angiography), autopsy, or through surgical means (index hospitalization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients transfused and the number of blood products and hemostatic products utilized (e.g. red cells, plasma, platelets, cryoprecipitate, factor VII) (index hospitalization)</measure>
    <time_frame>Up to hospital discharge or postoperative day 28 (whichever occurs first)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset dialysis (since incident surgery) status</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary revascularization</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Utilization</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3592</enrollment>
  <condition>Disorder; Heart, Functional, Postoperative, Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Restrictive transfusion strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is &lt;75 g/L (&lt;7.5 g/dL;&lt;4.7mmol/L) intraoperatively and/or postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal transfusion strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is &lt;95 g/L (&lt;9.5 g/dL&lt;5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or &lt;85 g/L (&lt; 8.5 g/dL;&lt;5.3mmol/L) on the ward.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Restrictive Transfusion Strategy</intervention_name>
    <arm_group_label>Restrictive transfusion strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liberal transfusion strategy</intervention_name>
    <arm_group_label>Liberal transfusion strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Planned cardiac surgery using cardiopulmonary bypass

          -  Informed consent obtained

          -  Preoperative European System for Cardiac Operative Risk Evaluation (EuroSCORE I) of 6
             or more

        Exclusion Criteria:

          -  Patients who are unable to receive or who refuse blood products

          -  Patients who are involved in the autologous pre-donation program

          -  Patients who are having a heart transplant or having surgery solely for an insertion
             of a ventricular assist device

          -  Pregnancy or lactation (a negative pregnancy test must be obtained prior to
             randomization for women of childbearing potential.)

          -  Patients who are unable to receive or who refuse blood products
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mazer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadine Shehata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Whitlock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean Fergusson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Thorpe, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McVagh</last_name>
      <phone>204.233.8563</phone>
    </contact>
    <investigator>
      <last_name>Hilary Grocott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmage Crescini</last_name>
      <phone>416-864-6060</phone>
      <email>crescinic@smh.ca</email>
    </contact>
    <investigator>
      <last_name>David Mazer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Transfusion</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
